Skip to main content

Table 1 Distribution of clinical and epidemiological characteristics of the 113 patients included in the historical cohort and univariate analysis of risk

From: Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study

Cohort description

Univariate risk analysis

Patients’ features

Distribution

N. of events

Person-days at risk

Rate (95%CI)

RR (95%CI)

p-value

Sex

Male

65 (57.52%)

121

32675

3.70 (2.71-5.19)

1.00

 

Female

48 (42.48%)

60

22248

2.70 (1.71-4.50)

0.73 (0.38-1.40)

0.342

Age

<60

60 (53.10%)

127

29824

4.26 (3.16-5.86)

1.00

 

60 or more

53 (47.90%)

54

25099

2.15 (1.33-3.70)

0.49 (0.26-0.93)

0.028

Nadir A

≥ 0.13 ×109 /L

85 (75.22%)

104

41183

2.53 (1.82-3.59)

1.00

 

<0.13 Ă—109 /L

28 (24.78%)

77

1374

5.60 (3.83-8.51)

2.04 (1.02-4.05)

0.042

GVHD

No

98 (86.73%)

141

47756

2.95 (2.20-4.06)

1.00

 

Yes

15 (13.27%)

40

7167

5.58 (3.38-9.79)

2.18 (0.88-5.44)

0.090

HIV

Neg

103 (91.15%)

153

50914

3.01 (2.28-4.05)

1.00

 

Pos

10 (8.85%)

28

4009

6.98 (3.45-15.35)

3.13 (1.06-9.24)

0.039

Relapse

No

93 (82.30%)

138

45537

3.03 (2.27-4.13)

1.00

 

Yes

20 (17.70%)

43

9386

4.58 (2.56-8.92)

1.81 (0.79-4.15)

0.163

Protocol

R alone

20 (17.70%)

25

10362

2.41 (1.26-5.26)

1.00

 

R and CHT

56 (49.56%)

69

25417

2.71 (1.76-4.37)

1.60 (0.68-3.77)

 

R and auto HSCT

10 (8.85%)

11

545

2.02 (0.69-8.49)

0.84 (0.24-2.93)

 

R and allo HSCT

27 (23.89%)

76

13694

5.55 (3.85-8.27)

2.73 (1.08-6.94)

0.102

Disease

Indolent lymph. B

43 (38.05%)

45

21934

2.05 (1.28-3.50)

1.00

 

Aggressive lymph. C

53 (46.90%)

97

25188

3.85 (2.67-5.72)

2.31 (1.18-4.54)

 

Non-CD20 malig. D

17 (15.05%)

39

7801

5.00 (2.92-9.23)

2.95 (1.16-7.53)

0.024

Time

1st semester

113 E

108

18999

5.68 (4.20-7.89)

1.00

<0.001

2nd semester

99 E

40

18018

2.22 (1.43-3.65)

0.43 (0.30-0.63)

3rd semester

99 E

33

17906

1.84 (1.08-3.41)

0.36 (0.24-0.53)

Median R doses (iqr)

4 (2–6)

-

-

-

0.95 (0.84-1.08)

0.471

Mean days between doses (iqr)

17 (9–19)

-

-

-

0.99 (0.97-1.02)

0.664

Median days with <1000 ly (iqr)

38 (0–220)

-

-

-

1.00 (1.00-1.00)

0.946

Overall

113 (100%)

181

54923

3.30 (2.54-4.34)

  
  1. N number, HSCT hematopoietic stem cells transplant, HIV antibody against human immunodeficiency virus, GVHD graft versus host disease, R Rituximab, CHT chemotherapy, IQR inter-quartile range, RR rate ratio, 95%CI 95% confidence interval.
  2. A) 0.13x109/L lymphocytes represents the lowest quartiles limit; B) This includes: 19 follicular lymphomas; 11 chronic lymphatic leukaemias; 6 lymphoplasmacytic lymphomas; 3 mantle cell lymphomas; 2 multiple myelomas; 2 marginal zone lymphomas. C) This includes: 30 diffuse large cell B lymphomas; 8 acute lymphatic leukemias/lymphomas; 7 Burkitt's lymphomas; 4 post transplant lymphomatous diseases; 2 primary central nervous system lymphomas; 2 Castleman's diseases. D) This includes: 11 myeloid leukaemias, 5 Hodgkin lymphomas, 1 T-lymphoma; E) The figure represent the number of patients at the start of the semester since the first R administration.